ATE439856T1 - USE OF PEPTIDES DERIVED FROM THE B BETA CHAIN OF HUMAN FIBRINOGENE FOR THE TREATMENT OF SHOCK - Google Patents

USE OF PEPTIDES DERIVED FROM THE B BETA CHAIN OF HUMAN FIBRINOGENE FOR THE TREATMENT OF SHOCK

Info

Publication number
ATE439856T1
ATE439856T1 AT05752350T AT05752350T ATE439856T1 AT E439856 T1 ATE439856 T1 AT E439856T1 AT 05752350 T AT05752350 T AT 05752350T AT 05752350 T AT05752350 T AT 05752350T AT E439856 T1 ATE439856 T1 AT E439856T1
Authority
AT
Austria
Prior art keywords
sub
moiety
shock
treatment
peptide
Prior art date
Application number
AT05752350T
Other languages
German (de)
Inventor
Peter Petzelbauer
Kai Zacharowski
Original Assignee
Fibrex Medical Res & Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0108704A external-priority patent/AT414097B/en
Priority claimed from AT0004005A external-priority patent/AT501263B1/en
Application filed by Fibrex Medical Res & Dev Gmbh filed Critical Fibrex Medical Res & Dev Gmbh
Application granted granted Critical
Publication of ATE439856T1 publication Critical patent/ATE439856T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of a peptide of general Formula I wherein R<SUB>1 </SUB>and R<SUB>2</SUB>, being equal or different, denote hydrogen, a saturated or unsaturated hydrocarbon moiety comprising from 1 to 10, in particular from 1 to 3, carbon atoms, Z<SUB>1 </SUB>denotes a histidine or proline moiety, Z<SUB>2 </SUB>denotes an arginine moiety, a peptide moiety or a protein moiety comprising an initial arginine moiety, in particular comprising from 2 to 30 amino acids, which peptide has the biological property of matching the inducible VE-cadherin binding motif on the Bbeta-chain (i.e. Bbeta<SUB>15-42</SUB>) of human fibrin, for the preparation of a pharmaceutical preparation for the treatment of shock.
AT05752350T 2004-06-25 2005-06-24 USE OF PEPTIDES DERIVED FROM THE B BETA CHAIN OF HUMAN FIBRINOGENE FOR THE TREATMENT OF SHOCK ATE439856T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0108704A AT414097B (en) 2004-06-25 2004-06-25 Treatment of shock, e.g. due to bacterial toxins or hemorrhagic shock associated with viral infections, comprises using peptides matching the inducible VE-cadherin binding moiety of human fibrin Bbeta-chain
AT0004005A AT501263B1 (en) 2005-01-13 2005-01-13 Treatment of shock, e.g. due to bacterial toxins or hemorrhagic shock associated with viral infections, comprises using peptides matching the inducible VE-cadherin binding moiety of human fibrin Bbeta-chain
PCT/AT2005/000228 WO2006000007A1 (en) 2004-06-25 2005-06-24 Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock

Publications (1)

Publication Number Publication Date
ATE439856T1 true ATE439856T1 (en) 2009-09-15

Family

ID=35058593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05752350T ATE439856T1 (en) 2004-06-25 2005-06-24 USE OF PEPTIDES DERIVED FROM THE B BETA CHAIN OF HUMAN FIBRINOGENE FOR THE TREATMENT OF SHOCK

Country Status (20)

Country Link
US (1) US20080249006A1 (en)
EP (1) EP1691827B1 (en)
JP (1) JP2008503503A (en)
AT (1) ATE439856T1 (en)
AU (1) AU2005256121B2 (en)
BR (1) BRPI0506148A (en)
CA (1) CA2544676A1 (en)
CY (1) CY1109631T1 (en)
DE (1) DE502005007926D1 (en)
DK (1) DK1691827T3 (en)
EA (1) EA008799B1 (en)
ES (1) ES2331958T3 (en)
HK (1) HK1093308A1 (en)
HR (1) HRP20090618T1 (en)
IL (1) IL173969A (en)
NZ (1) NZ545634A (en)
PL (1) PL1691827T3 (en)
PT (1) PT1691827E (en)
SI (1) SI1691827T1 (en)
WO (1) WO2006000007A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502987A1 (en) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEMORRHAGIC SHOCK AND ITS AFFILIATES
WO2007095659A1 (en) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives, preparation thereof and the use thereof for preparing a therapeutic and/or preventative medicament
US20110098442A1 (en) * 2006-02-23 2011-04-28 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
DE602007002553D1 (en) * 2006-02-23 2009-11-05 Fibrex Medical Res & Dev Gmbh THEIR USE FOR THE PREPARATION OF A THERAPEUTIC AND / OR PROPHYLACTICALLY ACTIVE PHARMACEUTICAL COMPOSITION
JP2010540892A (en) * 2007-09-24 2010-12-24 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー Method for screening compound having anti-inflammatory activity
JP5410997B2 (en) * 2008-01-31 2014-02-05 則行 川村 Depression and depression markers and detection / diagnosis using them
US7884074B2 (en) 2008-05-15 2011-02-08 Ikaria Development Subsidiary Two, LLC Compounds and methods for prevention and/or treatment of inflammation using the same
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (en) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Agents for the treatment and / or prophylaxis of microcirculation disorders
CN1518558B (en) * 2000-12-12 2010-06-16 菲布雷克斯医疗研究及开发有限责任公司 Peptides and/or proteins and use thereof for production of therapeutic and/or prophylactic medicament
EP1420778B1 (en) * 2001-03-06 2006-11-22 Dorian Bevec Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
US20110098442A1 (en) * 2006-02-23 2011-04-28 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives as well as pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
DK1691827T3 (en) 2009-12-14
IL173969A (en) 2011-06-30
NZ545634A (en) 2009-09-25
AU2005256121A8 (en) 2008-08-21
AU2005256121B2 (en) 2011-03-03
HK1093308A1 (en) 2007-03-02
HRP20090618T1 (en) 2010-01-31
PL1691827T3 (en) 2010-01-29
EA200600561A1 (en) 2006-08-25
EA008799B1 (en) 2007-08-31
DE502005007926D1 (en) 2009-10-01
US20080249006A1 (en) 2008-10-09
ES2331958T3 (en) 2010-01-21
WO2006000007A1 (en) 2006-01-05
SI1691827T1 (en) 2010-01-29
CA2544676A1 (en) 2006-01-05
EP1691827B1 (en) 2009-08-19
EP1691827A1 (en) 2006-08-23
CY1109631T1 (en) 2014-08-13
JP2008503503A (en) 2008-02-07
PT1691827E (en) 2009-11-23
AU2005256121A1 (en) 2006-04-27
BRPI0506148A (en) 2006-10-24
IL173969A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
ATE439856T1 (en) USE OF PEPTIDES DERIVED FROM THE B BETA CHAIN OF HUMAN FIBRINOGENE FOR THE TREATMENT OF SHOCK
ATE527353T1 (en) PDGF-BINDING POLYPEPTIDE FROM PROTEIN A
DE602005020165D1 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
ME00185B (en) Specific binding agents of human angiopoietin-2
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
MX2008009493A (en) Novel peptide and use thereof.
AR036196A1 (en) MULTIMERIC CONTRACT AGENTS DIRECTED TO PEPTIDES
DE60223058D1 (en) COMPOSITIONS AND METHOD FOR TREATING DIABETES
NZ607892A (en) Tfpi inhibitors and methods of use
ATE368688T1 (en) PEPTIDES, THEIR PRODUCTION AND USE FOR BINDING IMMUNOGLOBULINS
DE60233532D1 (en) SYNTHETIC ODE APPLICATIONS BINDING TO PROTEIN PHOSPHATASE 2A
ATE455792T1 (en) NEW PHOSPHATE BINDING PROTEIN, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF
ATE490266T1 (en) PEPTIDES THAT PERMEATE INTO CELLS AS CARRIERS FOR MOLECULES
ATE362487T1 (en) PEPTIDES CONTAINING N-SUBSTITUTED L-AMINO ACIDS FOR THE PREVENTION OF BETA STRAND ASSOCIATION
DE60025480D1 (en) METHODS OF IDENTIFYING MODULATORS OF INTERCHANGEABLE PROTEINS
ATE550345T1 (en) SFRP, SFRP-INTERACTING PEPTIDE MOTIVES AND METHODS OF USE
ATE485831T1 (en) TREATMENT OF NEURODEGENERATION
UA91497C2 (en) Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock
DE60234843D1 (en) MODIFIED PEPTIDES AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
HK1083850A1 (en) Peptides binding the phosphatase 2a protein and polynucleotides encoding same
GB0426960D0 (en) TGR-3 like protein receptor
AR062762A1 (en) METHODS TO PROMOTE COLLATERAL VASCULARIZATION WITHOUT LEAKS
WO2005087809B1 (en) Peptides from vitronectin and their therapeutic exploitation for osteoblast adhesion
NZ591989A (en) Prion-specific peptide reagents